EFFECTS OF RISING SINGLE ORAL DOSES OF L-706,000 ON CORON. ART. DISEASE

这项随机、双盲、安慰剂对照、多中心研究将 测试以下假设：1）口服L-706，000将 产生剂量相关的QTC间期（QT间期）延长 校正心率），和2）口服L-706，000将 在冠状动脉疾病患者中安全且耐受性良好。

This randomized, double-blind, placebo-controlled, multicenter study will test the following hypotheses: 1) oral administration of L-706,000 will produce a dose-related prolongation of the QTC interval (QT interval corrected for heart rate), and 2) oral administration of L-706,000 will be safe and well-tolerated in patients with coronary artery disease.